Welcome to IsraPharm - Contact us at +972 7337 468 45 (Office)

Contact Us

Office Address

Weizman 14 st., Tel Aviv, Israel

Phone Number

+972 7337 46845 (Office)

Email Address

[email protected]



In Stock

Add to Wishlist
Add to Wishlist


Puma Biotechnology’s Nerlynx was recently approved by the FDA for extended adjuvant treatment of HER2-positive early-stage breast cancer. It is the first drug for extended adjuvant treatment for patients with this pathology, allowing to reduce the risk of recurrence.

Active ingredient: neratinib

Prescription medicine